Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 26;17(1):19-30.
doi: 10.1007/s40200-018-0334-x. eCollection 2018 Jun.

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Fatemeh Khatami  1 , Seyed Mohammad Tavangar  1   2
Affiliations
Review

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Fatemeh Khatami et al. J Diabetes Metab Disord. .

Abstract

The heterogeneity of tumor is considered as a major difficulty to victorious personalized cancer medicine. There is an extremeneed of consistent response evaluation for in vivo tumor heterogeneity anditscoupledconflict mechanisms. In this occasion researchers will be able to keep pace withpredictive, preventive, personalized, and Participatory (P4) medicine for cancer managements. In fact tumor heterogeneity is a central part of cancer evolution,soin order to progress in understanding of the dynamics within a tumor some diagnostic apparatus should be improved. Latest molecular techniques like Next generation Sequencing (NGS) and ultra-deep sequencing could disclose some clones within a liquid tumor biopsy which mainly responsible of treatment resistance. Circulating tumor DNA (ctDNA) as a main component of liquid biopsy is agifted biomarker for cancer mutation tracking as well as profiling. Personalized medicine facilitate learning regarding to genetic pools of tumor and their possible respond to treatment which could be much easier by using of ctDNA.With this information, cliniciansarelooking forward to find the best strategies for prevention, screening, and treatment in the way of precision medicine. Currently, numerous clinical efficacy of such informative improved treatment are in hand. Here we represent the review of plasma-derived ctDNA studies use in personalized cancer managements.

Keywords: Cancer; Circulating tumor DNA (ctDNA); Personalized medicine.

PubMed Disclaimer

Conflict of interest statement

This manuscript does not report on or involve the use of any animal or human data or tissue, so ethical approval is not applicable in this section.This review article does not contain data from any individual person; consequently the consent for publication is “Not applicable” in this section.All authors declare that they have no competing interests” in this section.

Figures

Fig. 1
Fig. 1
The “beads-on-a-string” structure taken from slide share (http://slideplayer.com/slide/5675348/). It is composed of eight specific histones come together (octamer). The linker DNA length is about 150 base pairs which are next to the ctDNA length
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Larijani B, Shirzad M, Mohagheghi M, Haghpanah V, Mosavi-Jarrahi A, Tavangar S, et al. Epidemiologic analysis of the Tehran cancer institute data system registry (TCIDSR) Asian Pac J Cancer Prev. 2004;5(1):36–39. - PubMed
    1. Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi A, Tavangar S, Malekzadeh R, Larijani B. Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer. 2006;43(2):80–85. - PubMed
    1. Underhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, Baker DN, et al. Fragment length of circulating tumor DNA. PLoS Genet. 2016;12(7):e1006162. - PMC - PubMed
    1. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011;11(6):426–437. - PubMed
    1. Stroun M, Anker P. Nucleic acids spontaneously released by living frog auricles. Biochem J. 1972;128(3):100P. - PMC - PubMed

LinkOut - more resources